TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02763202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHS Transition Services
Description: The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge
Study: NCT01535456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLT-PET scans
Description: FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
Study: NCT00977821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oocyte Vitrification
Study: NCT02381639

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment
Description: The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment
Description: The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
Study: NCT01119300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm
Description: Loading and monitoring dose according to genotype-guided dosing algorithm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study: NCT03639909

Intervention type: PROCEDURE
Intervention: sweating function
Description: Sweating dysfunction by Sudoscan

Intervention type: PROCEDURE
Intervention: sweating function
Description: Sweating dysfunction by Sudoscan

Intervention type: PROCEDURE
Intervention: Cardiovascular function
Description: Cardiovascular (CV) tests

Intervention type: PROCEDURE
Intervention: Cardiovascular function
Description: Cardiovascular (CV) tests
Study: NCT03912519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parallel placement of 16 gauge electrodes
Description: Parallel technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perpendicular placement with 22 gauge electrodes
Description: Perpendicular technique
Study: NCT01516086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID
Study: NCT00517829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
Study: NCT01516086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate (FP)
Description: FP Inhalation BID
Study: NCT00357669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 25 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 25 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study: NCT00517829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Eloxatin 130 mg/m2 IV over 2 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Eloxatin 130 mg/m2 IV over 2 hours
Study: NCT01426139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention Biotronik Orsiro DES
Description: Stenting
Study: NCT00576043

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulator Training
Description: 3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
Study: NCT01097278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT02443883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT00357669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 50 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study: NCT02443883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT02343172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study: NCT02008682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
Study: NCT00357669

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo Pharmaceutical Form: Tablet~* Concentration: 25 mg and 50 mg~* Route of Administration: Oral use
Study: NCT00531791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone group
Description: Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
Study: NCT02008682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
Study: NCT01179009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).
Study: NCT00531791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair group
Description: Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
Study: NCT00312195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
Study: NCT01179009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Controlled IV ketamine infusion (0.00225mg/kg-min. \[18% (0.0125 mg/kg-min.).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: IV saline (i.e. placebo ketamine)
Study: NCT00345176

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/zeaxanthin
Description: 10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA/EPA
Description: Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/zeaxanthin and DHA/EPA
Description: 10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Study: NCT02202876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: 1.75 gm/kg to a maximum of 75 gm of an oral glucose solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: 1.75 gm/kg to a maximum of 75 gm of an oral glucose solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: 1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
Study: NCT00312195

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match BTDS
Description: Placebo to match buprenorphine transdermal patch applied for 7-day wear.
Study: NCT04721301

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab plus Maraviroc
Description: In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc
Study: NCT01322282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
Study: NCT02202876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: 1.75 gm/kg to a maximum of 75 gm of an oral glucose solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Glycemic Index Meal
Description: isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat
Study: NCT01322282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
Study: NCT02202876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Index Meal
Description: isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Soda
Description: Test soda containing 60% fructose and 40% glucose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit juice
Description: Fruit juice containing a combination fructose, glucose, and sucrose at a dose of 1.75 grams per kilogram body weight to a maximum of 75 grams
Study: NCT01600443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric
Description: Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric
Description: Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric
Description: Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric
Description: Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric
Description: Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric
Description: Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Description: Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Description: Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Description: Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Description: Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Description: Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Description: Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
Study: NCT04631146

Intervention type: DRUG
Intervention: Camrelizumab
Description: PD-1 inhibitors
Study: NCT03472157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle therapy
Description: Lifestyle habits (caloric intake and exercise) + pedometer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy
Study: NCT03080246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training Exercise
Study: NCT01997411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Glucagon
Study: NCT02563847

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 0.52 g L-Tryptophan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Tryptophan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.56 g L-Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 50 g Xylitol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 75 g Erythritol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 75 g Glucose
Study: NCT03655249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosoltherapy
Description: Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosoltherapy
Description: Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
Study: NCT02563847

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 300 mL tap water
Study: NCT04293822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Cetrizine 1% gel, which will be prepared at the department of Pharmaceutics, Faculty of Pharmacy, Assiut University in the form of Nano-transferosomes (NTF).
Study: NCT02563847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg 13C-sodium acetate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg 13C-sodium acetate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg 13C-sodium acetate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg 13C-sodium acetate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg 13C-sodium acetate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 50 mg 13C-sodium acetate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 50 mg 13C-sodium acetate
Study: NCT04293822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: The patients will be randomly divided into 2 groups; each group contains 30 patients. Patients in both groups will be given the treatment in identical non-labeled bottles with a code and neither the patient nor the doctor will know which treatment is given and what the code referred to. The patients will be instructed to use the treatment twice daily for 6 month duration.~This group will use Minoxidil 5% gel
Study: NCT03238495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere, Carboplatin, Herceptin + Pertuzumab
Description: TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere, Carboplatin, Herceptin + Pertuzumab
Description: TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
Study: NCT03645993

Intervention type: GENETIC
Intervention: Genetic Testing
Description: A one time blood sample will be taken.
Study: NCT03821857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-F-Flortaucipir
Description: Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Study: NCT03563378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: Patients will be administered Lactated Ringer's solution for intraoperative fluid management.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Patients will be administered normal saline for intraoperative fluid management.
Study: NCT03182270

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nCLE
Description: Procedure: EUS-FNA Device: nCLE
Study: NCT00205855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision SCS
Description: Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
Study: NCT02164461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axalimogene filolisbac

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axalimogene filolisbac
Study: NCT00265538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient educational letter to engage provider in hypertension rx discussion
Description: Patients will receive a customized/tailored letter (education) including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s). All the intervention arms (A, B and C) receive the letter.
Study: NCT02164461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axalimogene filolisbac
Study: NCT04296448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellscope
Description: Cellphone otoscope (Cellscope) to evaluate pediatric patient ears.